Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses a triplet of chemotherapy, trastuzumab, and pertuzumab in the adjuvant and neoadjuvant settings.
Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses a triplet of chemotherapy, trastuzumab, and pertuzumab in the adjuvant and neoadjuvant settings. Beitsch argues that pertuzumab should be included in the triplet due to its prolonging survival in patients with HER2-positive breast cancer that have the 80-gene Luminal subtype.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen